Takeda Pharmaceutical Co., Ltd.

Takeda Pharmaceutical Company Limited American Depositary Receipt (ADR) represents ownership in Takeda Pharmaceutical Company Limited, a leading global pharmaceutical firm headquartered in Tokyo, Japan. The ADR facilitates access for international investors, providing exposure to Takeda’s shares through negotiable certificates issued in the United States, with each ADR representing a fraction of the underlying ordinary share (specifically, two ADRs correspond to one ordinary share). Takeda’s primary function is the research, development, manufacture, and marketing of a broad portfolio of innovative pharmaceuticals, over-the-counter drugs, and healthcare products, addressing key therapeutic areas such as gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, neuroscience, and vaccines. The company’s products and pipeline span treatments for life-limiting and rare diseases, complex chronic conditions, and critical global health needs. As one of the world’s largest biopharmaceutical companies, Takeda’s ADRs play a significant role in broadening global investor access and enhancing liquidity in the market, representing the company’s international presence and strategic importance in the healthcare and pharmaceutical sectors.